Denali Therapeutics Inc.
Denali Therapeutics Inc. (DNLI) is a publicly traded company in the Unknown sector. Across all available filings, 24 corporate insiders have executed 704 transactions totaling $467.6M, demonstrating a bearish sentiment with -$457.7M in net insider flow. The most recent transaction on Sep 3, 2025 involved a transaction of 50,000 shares valued at $0.
DNLI Insider Activity Summary
Who Is Buying DNLI Stock?
No significant insider buying has been recorded for DNLI in the recent period.
Who Is Selling DNLI Stock?
No significant insider selling has been recorded for DNLI in the recent period.
Is Denali Therapeutics Inc. Insider Trading Bullish or Bearish?
Based on recent SEC filings, insider sentiment for DNLI is bearish with an Insider Alignment Score of 1/100 and a net flow of -$457.7M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
DNLI Frequently Asked Questions
Understanding DNLI Insider Activity
Insider trading at Denali Therapeutics Inc. (DNLI) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 24 insiders are actively trading DNLI stock, having executed 704 transactions in the past 90 days. The most active insider is Douglas K. Bratton (Executive), who has made 7 transactions totaling $150.4M.
Related Tools
Track Denali Therapeutics Inc. Insider Activity
Get notified when executives and directors at DNLI file new Form 4 transactions